FDA Approves Desmopressin Acetate Oral Solution for Central Diabetes Insipidus

The FDA has approved desmopressin acetate oral solution (Desmoda; Eton Pharmaceuticals) for the treatment of central diabetes insipidus (CDI), marking an important advancement in the management of a rare endocrine disorder that requires careful and individualized therapy.¹ The approval introduces a liquid formulation of desmopressin designed to address long-standing challenges associated with dosing precision and administration across pediatric and adult populations.¹ The therapy was previously developed under the investigational designation ET-600 and supported by positive pivotal clinical study results demonstrating bioequivalence and favorable pharmacokinetic performance.²

CDI is characterized by a deficiency of arginine vasopressin (antidiuretic hormone), resulting in excessive urination and thirst. Effective long-term management hinges on careful titration of desmopressin to align with each patient’s diurnal pattern of water balance. However, existing formulations have historically presented limitations related to dose flexibility and administration, particularly in younger patients or those requiring fine adjustments.¹

“Desmoda represents one of the most important product launches in Eton’s history. It builds on our strategy of delivering differentiated therapies to [patients with rare endocrine conditions]. By leveraging our existing pediatric endocrinology platform, we believe Desmoda has the potential to become a foundational therapy in this category,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals, in a news release.¹

Brynjelsen further emphasized the clinical implications of the new formulation. “In central diabetes insipidus, effective long-term management depends on accurately matching desmopressin dosing to each patient’s diurnal pattern of water balance. Historically, clinicians have primarily relied on formulations that were not designed for fine dose adjustments or had other administration issues, and both clinicians and families often had to rely on work-arounds. Desmoda introduces a liquid solution designed to deliver individualized dosing precision and consistency for patients across the age spectrum.”¹

Clinical Data Supporting Approval

The FDA approval was supported by data from a pivotal clinical study evaluating the investigational candidate ET-600. According to Eton Pharmaceuticals, the study met its primary end points, demonstrating bioequivalence to the reference listed drug and supporting its pharmacokinetic comparability. These results provided the necessary clinical foundation for regulatory review and subsequent approval.²

Expert Perspectives on Individualized Management

Clinicians and patient advocacy leaders have highlighted the practical importance of a liquid desmopressin option in CDI management.

“Central diabetes insipidus requires careful, individualized management, where dosing precision and flexibility truly matter. Having a liquid formulation of desmopressin has the potential to meaningfully support how we initiate and manage therapy. It’s encouraging to see innovation that directly addresses real-world challenges faced by clinicians and families and gives greater confidence when tailoring treatment across age groups,” said Lewis Blevins, MD, professor of medicine and neurological surgery at the University of California, San Francisco (UCSF) School of Medicine and medical director of the California Center for Pituitary Disorders at UCSF Medical Center.¹

From a patient advocacy perspective, consistent and accurate dosing remains paramount. “For families living with central diabetes insipidus/AVP-D [arginine vasopressin deficiency], treatment demands precision, consistency, and careful management of dosing. A liquid option like Desmoda is a meaningful improvement because it helps make sure that the dose is always right, every time. This is very important in cases where the wrong dose can have a big impact," said Muriël Marks, board member of Worldwide Adrenal and Pituitary Organizations.¹

Implications for Pharmacy Practice

For pharmacists, the approval of desmopressin acetate oral solution introduces a new tool in CDI management that may enhance dosing accuracy and patient counseling. Education on appropriate administration, monitoring for signs of hyponatremia, and reinforcing adherence will remain critical components of care.

The launch reflects continued industry investment in differentiated therapies for niche patient populations.¹ The addition of a liquid desmopressin formulation designed for individualized dosing may represent a meaningful evolution in CDI treatment paradigms, offering clinicians and families a formulation tailored to the practical realities of long-term disease management.

REFERENCES

1. Eton Pharmaceuticals announces U.S. FDA approval for Desmoda (desmopressin acetate) oral solution. News release. Eton Pharmaceuticals, Inc. February 25, 2026. Accessed February 26, 2026. https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-us-fda-approval-desmodatm

2. Eton Pharmaceuticals announces positive pivotal clinical study results for product candidate ET-600. News release. Eton Pharmaceuticals, Inc. March 14, 2025. Accessed February 26, 2026. https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-positive-pivotal-clinical-study#xd_co_f=ZTY1ZjA2MjAtMjJiZC00NTY3LWE4N2EtMTQzMjg5YmY3ZWUw~